



US005744133A

United States Patent [19]

Lathe et al.

[11] Patent Number: 5,744,133

[45] Date of Patent: Apr. 28, 1998

[54] **EXPRESSION OF A TUMOR-SPECIFIC ANTIGEN BY A RECOMBINANT VECTOR VIRUS AND USE THEREOF IN PREVENTITIVE OR CURATIVE TREATMENT OF THE CORRESPONDING TUMOR**

[75] Inventors: **Richard Lathe; Marie-Paule Kieny**, both of Strasbourg; **Guerrino Meneguzzi**, Nice, all of France

[73] Assignee: **Transgene S.A.**, France

[21] Appl. No.: **357,138**

[22] Filed: **Dec. 15, 1994**

Related U.S. Application Data

[63] Continuation of Ser. No. 248,463, May 24, 1994, abandoned, which is a continuation of Ser. No. 126,021, Sep. 24, 1993, abandoned, which is a continuation of Ser. No. 984,242, Dec. 1, 1992, abandoned, which is a continuation of Ser. No. 546,318, Jul. 2, 1990, abandoned, which is a continuation-in-part of Ser. No. 84,852, Aug. 13, 1987, abandoned.

[30] Foreign Application Priority Data

Aug. 13, 1986 [FR] France 86 11700
Mar. 6, 1989 [FR] France 89 02897

[51] **Int. Cl.⁶** **A01N 63/00**; C12N 15/86; C12N 7/01; C12N 7/04

[52] **U.S. Cl.** **424/93.2**; 424/93.6; 435/235.1; 435/320.1

[58] **Field of Search** 435/320.1, 235.1; 424/93.2, 93.6

[56] References Cited

U.S. PATENT DOCUMENTS

4,603,112 7/1986 Paoletti et al. 435/235

OTHER PUBLICATIONS

Cason et al. "Toward Vaccines Against Human Papillomavirus type-16 Genital Infections" *Vaccine* 11(6): 603-611 1993.

Rassoulzadegan et al., The roles of individual polyoma virus early proteins in oncogenic transformation. *Nature*, vol. 300, 23/30 Dec. 1982, pp. 713-718.

Tyndall et al., A region of the polyoma virus genome between the replication origin and late protein coding sequences is required in cis for both early gene expression and viral DNA replication. *Nucleic Acids Research*, vol. 9, No. 23, 1981, pp. 6231-6251.

Food and Drug Administration, HHS, 21 CFR Sections 620.1-620.33.

Treisman et al., Transformation of rat cells by an altered polyoma virus genome expressing only the middle-T protein. *Nature*, vol. 292, Aug. 13, 1981, pp. 595-600.

Primary Examiner—Nancy Degen

Attorney, Agent, or Firm—Cushman Darby & Cushman IP Group of Pillsbury Madison & Sutro LLP

[57] ABSTRACT

The invention concerns a vector being vaccinia virus, which comprises a heterologous DNA sequence which codes at least for the essential region of a tumor specific protein called T antigen, cloned within a non essential region of the vaccinia virus, as well as regulatory element required for the expression of said DNA sequence in higher cells, the vector is particularly useful as a pharmaceutical composition having a preventive or creative activity against tumors especially tumors caused by a papillomavirus.

26 Claims, 10 Drawing Sheets